SARS-CoV-2 infection and recurrence of anti-glomerular basement disease: a case report

BMC Nephrol. 2021 Feb 27;22(1):75. doi: 10.1186/s12882-021-02275-4.

Abstract

Background: Anti-glomerular basement membrane disease (GBM) disease is a rare autoimmune disease causing rapidly progressive glomerulonephritis and pulmonary haemorrhage. Recently, an association between COVID-19 and anti-glomerular basement membrane (anti-GBM) disease has been proposed. We report on a patient with recurrence of anti-GBM disease after SARS-CoV-2 infection.

Case presentation: The 31-year-old woman had a past medical history of anti-GBM disease, first diagnosed 11 years ago, and a first relapse 5 years ago. She was admitted with severe dyspnoea, haemoptysis, pulmonary infiltrates and acute on chronic kidney injury. A SARS-CoV-2 PCR was positive with a high cycle threshold. Anti-GBM autoantibodies were undetectable. A kidney biopsy revealed necrotising crescentic glomerulonephritis with linear deposits of IgG, IgM and C3 along the glomerular basement membrane, confirming a recurrence of anti-GBM disease. She was treated with steroids, plasma exchange and two doses of rituximab. Pulmonary disease resolved, but the patient remained dialysis-dependent. We propose that pulmonary involvement of COVID-19 caused exposure of alveolar basement membranes leading to the production of high avidity autoantibodies by long-lived plasma cells, resulting in severe pulmonary renal syndrome.

Conclusion: Our case supports the assumption of a possible association between COVID-19 and anti-GBM disease.

Keywords: Anti-GBM disease; COVID-19; Case report; Glomerulonephritis; SARS-CoV-2.

Publication types

  • Case Reports

MeSH terms

  • Anti-Glomerular Basement Membrane Disease / diagnosis*
  • Anti-Glomerular Basement Membrane Disease / etiology
  • Anti-Glomerular Basement Membrane Disease / physiopathology
  • Anti-Glomerular Basement Membrane Disease / therapy
  • COVID-19 / complications*
  • Child
  • Cyclophosphamide / therapeutic use
  • Female
  • Glucocorticoids / therapeutic use
  • Humans
  • Immunosuppressive Agents / therapeutic use
  • Kidney / pathology
  • Kidney / physiology
  • Methylprednisolone / therapeutic use
  • Plasmapheresis
  • Prednisone / therapeutic use
  • Recurrence
  • SARS-CoV-2
  • Urinary Bladder / physiopathology
  • Vesico-Ureteral Reflux / physiopathology

Substances

  • Glucocorticoids
  • Immunosuppressive Agents
  • Cyclophosphamide
  • Prednisone
  • Methylprednisolone